{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:23:13Z","timestamp":1787779393856,"version":"build-2784847793"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002380","name":"Hanyang University","doi-asserted-by":"publisher","award":["HY-2025-1103"],"award-info":[{"award-number":["HY-2025-1103"]}],"id":[{"id":"10.13039\/501100002380","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00217123"],"award-info":[{"award-number":["RS-2023-00217123"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1F1A1075439"],"award-info":[{"award-number":["2022R1F1A1075439"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.amjmed.2026.05.004","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:53:18Z","timestamp":1778025198000},"page":"1337-1347.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bleeding-related interactions between DOACs and cardiovascular drugs: Insights from FDA adverse event reporting system"],"prefix":"10.1016","volume":"139","author":[{"given":"Seunghyun","family":"Cheon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Seon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Seo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5608-1530","authenticated-orcid":false,"given":"Jee-Eun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.amjmed.2026.05.004_bib0001","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amjmed.2026.05.004_bib0002","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.amjmed.2026.05.004_bib0003","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.amjmed.2026.05.004_bib0004","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.amjmed.2026.05.004_bib0005","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s10557-022-07336-w","article-title":"Efficacy and safety of direct oral anticoagulants (DOACs) versus Warfarin in atrial fibrillation patients with prior stroke: a systematic review and meta-analysis","volume":"37","author":"Umashankar","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"10.1016\/j.amjmed.2026.05.004_bib0006","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13498","article-title":"Integrated care and outcomes in patients with atrial fibrillation and comorbidities","volume":"51","author":"Proietti","year":"2021","journal-title":"Eur J Clin Invest"},{"issue":"12","key":"10.1016\/j.amjmed.2026.05.004_bib0007","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/jcph.2106","article-title":"Gastrointestinal bleeding during direct oral anticoagulant therapy in patients with nonvalvular atrial fibrillation and risk of polypharmacy","volume":"62","author":"Honda","year":"2022","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.amjmed.2026.05.004_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2020-001257","article-title":"Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis","volume":"7","author":"Gallagher","year":"2020","journal-title":"Open Heart"},{"issue":"12","key":"10.1016\/j.amjmed.2026.05.004_bib0009","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s40262-020-00954-3","article-title":"Correction to: drug-drug interactions with direct oral anticoagulants","volume":"59","author":"Foerster","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.amjmed.2026.05.004_bib0010","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s11239-020-02037-3","article-title":"The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding","volume":"49","author":"Hanigan","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"10.1016\/j.amjmed.2026.05.004_bib0011","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11239-018-1738-7","article-title":"Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients","volume":"46","author":"Hirsh Raccah","year":"2018","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"10.1016\/j.amjmed.2026.05.004_bib0012","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.amjmed.2018.10.008","article-title":"Concomitant use of direct oral anticoagulants with antiplatelet agents and the risk of major bleeding in patients with nonvalvular atrial fibrillation","volume":"132","author":"Douros","year":"2019","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.amjmed.2026.05.004_bib0013","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.amjmed.2025.06.034","article-title":"Outcomes of oral anticoagulation with concomitant NSAID use: a registry based cohort study","volume":"138","author":"Ardeshna","year":"2025","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.amjmed.2026.05.004_bib0014","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2174\/0113894501290296240327081624","article-title":"Drug repurposing using FDA adverse event reporting System (FAERS) database","volume":"25","author":"Morris","year":"2024","journal-title":"Curr Drug Targets"},{"issue":"9","key":"10.1016\/j.amjmed.2026.05.004_bib0015","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3390\/ph18091311","article-title":"Analysis of upper gastrointestinal adverse events associated with oral anticoagulants and potential drug interactions with cardiovascular drugs: exploratory study using FDA adverse event reporting system","volume":"18","author":"Cheon","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.amjmed.2026.05.004_bib0016","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.amjmed.2026.05.004_bib0017","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjmed.2026.05.004_bib0018","unstructured":"United States Food and Drug Administration. FDA\u2019s examples of drugs that interact with CYP enzymes and transporter systems. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems, 2026 (accessed 16 February 2026)."},{"issue":"1","key":"10.1016\/j.amjmed.2026.05.004_bib0019","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/MCG.0000000000000432","article-title":"NSAID-induced gastrointestinal injury: a focused update for clinicians","volume":"50","author":"Scheiman","year":"2016","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"10.1016\/j.amjmed.2026.05.004_bib0020","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.amjcard.2019.01.027","article-title":"Bleeding risk of add-on anti-platelet agents to direct oral anticoagulants in patients with nonvalvular atrial fibrillation (From 2216 Patients in the DIRECT Registry)","volume":"123","author":"Sotomi","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2026.05.004_bib0021","doi-asserted-by":"crossref","DOI":"10.1155\/cdr\/9923772","article-title":"Effectiveness and safety of dose-specific DOACs in patients with atrial fibrillation: a systematic review and network meta-analysis","volume":"2025","author":"Oh","year":"2025","journal-title":"Cardiovasc Ther"},{"issue":"7","key":"10.1016\/j.amjmed.2026.05.004_bib0022","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/imj.70103","article-title":"2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri-operative and bleeding management","volume":"55","author":"Tran","year":"2025","journal-title":"Intern Med J"},{"issue":"3","key":"10.1016\/j.amjmed.2026.05.004_bib0023","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1474-4422(24)00519-2","article-title":"Direct oral anticoagulants versus vitamin K antagonists for cerebral venous thrombosis (DOAC-CVT): an international, prospective, observational cohort study","volume":"24","author":"van de Munckhof","year":"2025","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.amjmed.2026.05.004_bib0024","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/pharmaceutics14061120","article-title":"Drug-Drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice","volume":"14","author":"Ferri","year":"2022","journal-title":"Pharmaceutics"},{"issue":"9\u201310","key":"10.1016\/j.amjmed.2026.05.004_bib0025","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s002280000215","article-title":"Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs","volume":"56","author":"van Puijenbroek","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.amjmed.2026.05.004_bib0026","unstructured":"International Council for harmonization. Standardized MedDRA queries (SMQs). https:\/\/www.meddra.org\/how-to-use\/tools\/smqs, 2026 (accessed 16 February 2026)."},{"issue":"12","key":"10.1016\/j.amjmed.2026.05.004_bib0027","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/03913988211013366","article-title":"Impact of heart failure drug therapy on rates of gastrointestinal bleeding in LVAD recipients: an INTERMACS analysis","volume":"44","author":"Jennings","year":"2021","journal-title":"Int J Artif Organs"},{"issue":"2","key":"10.1016\/j.amjmed.2026.05.004_bib0028","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/ehf2.14277","article-title":"Predictors of bleeding events in acute decompensated heart failure patients with antithrombotic therapy: AURORA study","volume":"10","author":"Kawanami","year":"2023","journal-title":"ESC Heart Fail"},{"issue":"18","key":"10.1016\/j.amjmed.2026.05.004_bib0029","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jama.2024.3867","article-title":"Serious bleeding in patients with atrial fibrillation using Diltiazem with Apixaban or Rivaroxaban","volume":"331","author":"Ray","year":"2024","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.amjmed.2026.05.004_bib0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025723","article-title":"Concomitant use of diltiazem with direct oral anticoagulants and bleeding risk in atrial fibrillation","volume":"11","author":"Xu","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.amjmed.2026.05.004_bib0031","article-title":"Apixaban-induced spontaneous hemorrhagic cardiac tamponade","volume":"16","author":"Ambat","year":"2024","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.amjmed.2026.05.004_bib0032","article-title":"A possible drug-drug interaction between Eliquis and amiodarone resulting in hemopericardium","volume":"13","author":"Olagunju","year":"2021","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.amjmed.2026.05.004_bib0033","doi-asserted-by":"crossref","first-page":"769","DOI":"10.7326\/M22-3238","article-title":"Risk for bleeding-related hospitalizations during use of Amiodarone with Apixaban or Rivaroxaban in patients with atrial fibrillation: a retrospective cohort study","volume":"176","author":"Ray","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2026.05.004_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.111709","article-title":"Potential interactions between digoxin and direct oral anticoagulants: application of cohort & novel case-crossover designs","volume":"181","author":"Wong","year":"2025","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.amjmed.2026.05.004_bib0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.4086","article-title":"Comparative effectiveness and safety of oral anticoagulants by dementia status in older patients with atrial fibrillation","volume":"6","author":"Lin","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.amjmed.2026.05.004_bib0036","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12872-022-02580-2","article-title":"Impact of renin-angiotensin-aldosterone-system inhibitor drugs on mortality in patients with atrial fibrillation and hypertension","volume":"22","author":"Xu","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"issue":"10","key":"10.1016\/j.amjmed.2026.05.004_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.107291","article-title":"Renin-angiotensin-aldosterone system inhibitors as a risk factor for chronic subdural hematoma recurrence: a matter of debate","volume":"32","author":"Shimohigoshi","year":"2023","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"2","key":"10.1016\/j.amjmed.2026.05.004_bib0038","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3390\/pharmaceutics14020231","article-title":"Genetic factors of renin-angiotensin system associated with major bleeding for patients treated with direct oral anticoagulants","volume":"14","author":"Yee","year":"2022","journal-title":"Pharmaceutics"},{"issue":"8 Suppl B","key":"10.1016\/j.amjmed.2026.05.004_bib0039","first-page":"9","article-title":"The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition","volume":"13","author":"Atlas","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.amjmed.2026.05.004_bib0040","doi-asserted-by":"crossref","first-page":"9771","DOI":"10.1038\/s41598-022-13772-3","article-title":"Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects","volume":"12","author":"Tehrani","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.amjmed.2026.05.004_bib0041","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41598-017-00473-5","article-title":"Angiotensin II promotes the anticoagulant effects of rivaroxaban via angiotensin type 2 receptor signaling in mice","volume":"7","author":"Yang","year":"2017","journal-title":"Sci Rep"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326003888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326003888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:10:29Z","timestamp":1787778629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934326003888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0002934326003888"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.05.004","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bleeding-related interactions between DOACs and cardiovascular drugs: Insights from FDA adverse event reporting system","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}